<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03309657</url>
  </required_header>
  <id_info>
    <org_study_id>HREC/17/QRBW/117</org_study_id>
    <nct_id>NCT03309657</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid</brief_title>
  <official_title>A Prospective Pharmacokinetic Evaluation of the Plasma and Cerebrospinal Fluid Concentrations of a Single Dose Ceftolozane/Tazobactam in Infected Critically Ill Patients With an Indwelling External Ventricular Drain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brisbane and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Queensland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Brisbane and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ceftolozane/tazobactam is an emerging newly available antibiotic that has a broad spectrum of&#xD;
      activity, and could be potentially useful in the management of central nervous system&#xD;
      infections. However, data relating to penetration of ceftolozane/ tazobactam into the central&#xD;
      nervous system, where a barrier against drug distribution exists (i.e. blood brain barrier),&#xD;
      is currently limited. In critically ill patients this is all the more challenging as&#xD;
      achieving adequate antibiotic concentrations even in blood is difficult.&#xD;
&#xD;
      The aim of this study is to describe the concentrations achieved in the cerebrospinal fluid&#xD;
      (i.e. bodily fluid found surrounding and inside of the brain) and blood after a single dose&#xD;
      of ceftolozane/tazobactam administered in critically ill patients with an existing external&#xD;
      ventricular drain (i.e. a device used in neurosurgery that relieves elevated intracranial&#xD;
      pressure in the brain). It is planned that this information gained will help develop dosing&#xD;
      strategies that will achieve target concentrations that will successfully treat central&#xD;
      nervous system infections in the future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although relatively less frequent, Gram negative nosocomial meningitis and ventriculitis are&#xD;
      observed in critical care settings, often associated with brain trauma, brain surgery, spinal&#xD;
      fluid shunt after brain surgery, spinal abnormalities or severe urinary tract infections with&#xD;
      bacteraemia. Gram negative meningitis is particularly challenging for treatment, when reduced&#xD;
      susceptibility of some of the common etiologic bacteria is encountered (e.g. Acinetobacter&#xD;
      baumannii, Pseudomonas aeruginosa, Enterobacter aerogenes). Furthermore, the presence of the&#xD;
      blood brain barrier (BBB) has meant that the choice of systemic antibiotics is very&#xD;
      restricted due to the limited ability of many antibiotics to achieve adequate concentrations&#xD;
      in the cerebrospinal fluid (CSF). The poor CSF penetration may also contribute to an&#xD;
      accelerated rate of the emergence of resistant pathogens in some patients/units. A&#xD;
      significant proportion of Gram negative bacilli clinical isolates (from patients with&#xD;
      meningitis) are resistant to broad spectrum antibiotics such as the third or later generation&#xD;
      cephalosporins. With the wide spread use of these antibiotics, the incidence of resistant&#xD;
      nosocomial infections has increased. Thus, there is an acute need for novel antibiotics that&#xD;
      can achieve adequate concentrations in the CSF, while exhibiting an excellent spectrum of&#xD;
      activity.&#xD;
&#xD;
      Ceftolozane/tazobactam is an emerging newly available antibiotic that has a broad spectrum of&#xD;
      activity, and could be potentially useful in the management of Gram negative meningitis. As&#xD;
      compared to other commonly used beta lactam antibiotics, it exhibits superior antibacterial&#xD;
      activity against difficult to treat Gram negative organisms, such as Pseudomonas aeruginosa&#xD;
      and Enterobacteriaceae spp. It is relatively stable against various resistance mechanisms&#xD;
      encountered by other beta lactams, and may be useful in the treatment of multi-drug resistant&#xD;
      (MDR) infections. However, data relating to CSF penetration is limited. In the critically&#xD;
      ill, achieving adequate antibiotic exposure, especially against the high MIC of some Gram&#xD;
      negatives (e.g. Pseudomonas), is difficult even in plasma, let alone in CSF for which a&#xD;
      distribution barrier (i.e. BBB) exists. Thus, it is prudent to investigate the CSF&#xD;
      pharmacokinetics of this new drug before it is used 'off label' by clinicians without&#xD;
      supportive data.&#xD;
&#xD;
      This study will describe the plasma and CSF pharmacokinetics of a 3.0 g dose of&#xD;
      ceftolozane/tazobactam in critically ill patients with an indwelling external ventricular&#xD;
      drain (EVD). We will use a population pharmacokinetics approach to determine if altered&#xD;
      dosing or alternative modes of administration, such as prolonged infusion, should be&#xD;
      considered to improve plasma exposure. Given that direct administration into the CSF (e.g.&#xD;
      intraventricular route) is not only invasive but also may risk neurotoxicity, pharmacokinetic&#xD;
      studies should explore the extent of drug distribution into CSF with systemic administration.&#xD;
      There is no clinical data on the CSF penetration of ceftolozane/tazobactam in critically ill&#xD;
      patients at the moment, and as such, this is a highly valuable study.&#xD;
&#xD;
      Aim of the study is to describe the pharmacokinetics of a single dose of&#xD;
      ceftolozane/tazobactam in the plasma and CSF of critically ill patients with an indwelling&#xD;
      EVD.&#xD;
&#xD;
      The study investigators hypothesise:&#xD;
&#xD;
      The plasma PK of cefolozane/tazobactam may be altered in critically ill patients with an&#xD;
      indwelling EVD.&#xD;
&#xD;
      The distribution of ceftolozane/tazobactam into the CSF may be impaired by the blood brain&#xD;
      barrier.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label pharmacokinetic study where enrolled critically ill patients with infection receive a single dose of ceftolozane-tazobactam (in addition to other active therapy).</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Unbound Ceftolozane Exposure in the Plasma</measure>
    <time_frame>Samples collected from 0 to 8 hours post dose at &quot;0, 1, 2,4,6, &amp; 8 h post dose were use estimate area under the curve from time zero to infinity estimated by non-compartmental analysis</time_frame>
    <description>Unbound Ceftolozane Exposure in the plasma given by the area under the unbound concentration-time curve from time zero to infinity (AUC0-inf).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unbound Tazobactam Exposure in the Plasma</measure>
    <time_frame>Samples collected from 0 to 8 hours post dose at &quot;0, 1, 2,4,6, &amp; 8 h post dose were use estimate area under the curve from time zero to infinity estimated by non-compartmental analysis</time_frame>
    <description>Unbound Tazobactam Exposure in the plasma given by the area under the unbound concentration-time curve from time zero to infinity (AUC0-inf).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unbound Ceftolozane Exposure in the CSF</measure>
    <time_frame>Samples collected from 0 to 8 hours post dose at &quot;0, 1, 2,4,6, &amp; 8 h post dose were use estimate area under the curve from time zero to infinity estimated by non-compartmental analysis</time_frame>
    <description>Unbound Ceftolozane Exposure in the CSF given by the area under the unbound concentration-time curve from time zero to infinity (AUC0-inf).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unbound Tazobactam Exposure in the CSF</measure>
    <time_frame>Samples collected from 0 to 8 hours post dose at &quot;0, 1, 2,4,6, &amp; 8 h post dose were use estimate area under the curve from time zero to infinity estimated by non-compartmental analysis</time_frame>
    <description>Unbound Tazobactam Exposure in the CSF given by the area under the unbound concentration-time curve from time zero to infinity (AUC0-inf).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Ceftolozane Tazobactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infected patients with external intraventricular drain will receive a single dose of Ceftolozane/ tazobactam (3000mg) over 1 hour and will undergo blood , csf and urine sampling at specific times over an 8 hour period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane/tazobactam</intervention_name>
    <description>This is an observational pharmacokinetic study whereby patients received a single dose of ceftolozane/tazobactam and plasma and cerebrospinal fluid samples were subsequently collected and analyzed to described the pharmacokinetics.</description>
    <arm_group_label>Ceftolozane Tazobactam</arm_group_label>
    <other_name>ZERBAXA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with any infection requiring treatment with ceftolozane/tazobactam and who have&#xD;
        met the following criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  The presence of an indwelling external ventricular drain (EVD) or requiring EVD&#xD;
             insertion due to obstructive hydrocephalus/subarachnoid haemorrhage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected allergy to penicillins and cephalosporins&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Receiving renal replacement therapy&#xD;
&#xD;
          -  Glomerular filtration rate less than 10 mL/min&#xD;
&#xD;
          -  Receiving piperacillin/tazobactam or having received piperacillin/tazobactam in the&#xD;
             past 7 days before enrolment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason A Roberts, PhD BPharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brisbane and Womens Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2017</study_first_posted>
  <results_first_submitted>August 5, 2020</results_first_submitted>
  <results_first_submitted_qc>August 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2020</results_first_posted>
  <last_update_submitted>August 21, 2020</last_update_submitted>
  <last_update_submitted_qc>August 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal Brisbane and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Jason Roberts</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Ceftolozane</mesh_term>
    <mesh_term>Ceftolozane, tazobactam drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual participant data available to other researchers</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT03309657/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ceftolozane Tazobactam</title>
          <description>Infected patients with external intraventricular drain will receive a single dose of Ceftolozane/ tazobactam (3000mg) over 1 hour and will undergo blood , csf and urine sampling at specific times over an 8 hour period.&#xD;
Ceftolozane/tazobactam: IV ceftolozane 2000mg /tazobactam 1000mg once only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ceftolozane Tazobactam</title>
          <description>Infected patients with external intraventricular drain will receive a single dose of Ceftolozane/ tazobactam (3000mg) over 1 hour and will undergo blood , csf and urine sampling at specific times over an 8 hour period.&#xD;
Ceftolozane/tazobactam: IV ceftolozane 2000mg /tazobactam 1000mg once only</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" lower_limit="53.5" upper_limit="64.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75" lower_limit="65" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Creatinine</title>
          <units>micro-mole/litre</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.5" lower_limit="42.25" upper_limit="57.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Albumin</title>
          <units>g/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" lower_limit="21.25" upper_limit="25.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Acute Physiology and Chronic Health Evaluation (APACHE) II</title>
          <description>Acute Physiology and Chronic Health Evaluation II [APACHE II] score on ICU admission was calculated from 12 routine physiologic measurements using the standard approach. APACHE II score ranges from 1 to 71, with higher scores correlating with an increased risk of mortality. For a detailed description, please refer to Crit Care Med. 1985 Oct;13(10):818-29.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.5" lower_limit="14" upper_limit="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Unbound Ceftolozane Exposure in the Plasma</title>
        <description>Unbound Ceftolozane Exposure in the plasma given by the area under the unbound concentration-time curve from time zero to infinity (AUC0-inf).</description>
        <time_frame>Samples collected from 0 to 8 hours post dose at &quot;0, 1, 2,4,6, &amp; 8 h post dose were use estimate area under the curve from time zero to infinity estimated by non-compartmental analysis</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane Tazobactam</title>
            <description>Infected patients with external intraventricular drain will receive a single dose of Ceftolozane/ tazobactam (3000mg) over 1 hour and will undergo blood , csf and urine sampling at specific times over an 8 hour period.&#xD;
Ceftolozane/tazobactam: IV ceftolozane 2000mg /tazobactam 1000mg once only</description>
          </group>
        </group_list>
        <measure>
          <title>Unbound Ceftolozane Exposure in the Plasma</title>
          <description>Unbound Ceftolozane Exposure in the plasma given by the area under the unbound concentration-time curve from time zero to infinity (AUC0-inf).</description>
          <units>mg*h/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322.6" lower_limit="182.7" upper_limit="413.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Unbound Tazobactam Exposure in the Plasma</title>
        <description>Unbound Tazobactam Exposure in the plasma given by the area under the unbound concentration-time curve from time zero to infinity (AUC0-inf).</description>
        <time_frame>Samples collected from 0 to 8 hours post dose at &quot;0, 1, 2,4,6, &amp; 8 h post dose were use estimate area under the curve from time zero to infinity estimated by non-compartmental analysis</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane Tazobactam</title>
            <description>Infected patients with external intraventricular drain will receive a single dose of Ceftolozane/ tazobactam (3000mg) over 1 hour and will undergo blood , csf and urine sampling at specific times over an 8 hour period.&#xD;
Ceftolozane/tazobactam: IV ceftolozane 2000mg /tazobactam 1000mg once only</description>
          </group>
        </group_list>
        <measure>
          <title>Unbound Tazobactam Exposure in the Plasma</title>
          <description>Unbound Tazobactam Exposure in the plasma given by the area under the unbound concentration-time curve from time zero to infinity (AUC0-inf).</description>
          <units>mg*h/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1" lower_limit="35.7" upper_limit="79.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Unbound Ceftolozane Exposure in the CSF</title>
        <description>Unbound Ceftolozane Exposure in the CSF given by the area under the unbound concentration-time curve from time zero to infinity (AUC0-inf).</description>
        <time_frame>Samples collected from 0 to 8 hours post dose at &quot;0, 1, 2,4,6, &amp; 8 h post dose were use estimate area under the curve from time zero to infinity estimated by non-compartmental analysis</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane Tazobactam</title>
            <description>Infected patients with external intraventricular drain will receive a single dose of Ceftolozane/ tazobactam (3000mg) over 1 hour and will undergo blood , csf and urine sampling at specific times over an 8 hour period.&#xD;
Ceftolozane/tazobactam: IV ceftolozane 2000mg /tazobactam 1000mg once only</description>
          </group>
        </group_list>
        <measure>
          <title>Unbound Ceftolozane Exposure in the CSF</title>
          <description>Unbound Ceftolozane Exposure in the CSF given by the area under the unbound concentration-time curve from time zero to infinity (AUC0-inf).</description>
          <units>mg*h/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" lower_limit="18.8" upper_limit="128.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Unbound Tazobactam Exposure in the CSF</title>
        <description>Unbound Tazobactam Exposure in the CSF given by the area under the unbound concentration-time curve from time zero to infinity (AUC0-inf).</description>
        <time_frame>Samples collected from 0 to 8 hours post dose at &quot;0, 1, 2,4,6, &amp; 8 h post dose were use estimate area under the curve from time zero to infinity estimated by non-compartmental analysis</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane Tazobactam</title>
            <description>Infected patients with external intraventricular drain will receive a single dose of Ceftolozane/ tazobactam (3000mg) over 1 hour and will undergo blood , csf and urine sampling at specific times over an 8 hour period.&#xD;
Ceftolozane/tazobactam: IV ceftolozane 2000mg /tazobactam 1000mg once only</description>
          </group>
        </group_list>
        <measure>
          <title>Unbound Tazobactam Exposure in the CSF</title>
          <description>Unbound Tazobactam Exposure in the CSF given by the area under the unbound concentration-time curve from time zero to infinity (AUC0-inf).</description>
          <units>mg*h/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="1.6" upper_limit="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The duration of the study enrolment up to 24 hours.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ceftolozane Tazobactam</title>
          <description>Infected patients with external intraventricular drain will receive a single dose of Ceftolozane/ tazobactam (3000mg) over 1 hour and will undergo blood , csf and urine sampling at specific times over an 8 hour period.&#xD;
Ceftolozane/tazobactam: IV ceftolozane 2000mg /tazobactam 1000mg once only</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Jason Roberts</name_or_title>
      <organization>University of Queensland Center for Clinical Research</organization>
      <phone>+61 7 334 65032</phone>
      <email>j.roberts2@uq.edu.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

